276 related articles for article (PubMed ID: 29458237)
1. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Park IH; Im SA; Jung KH; Sohn JH; Park YH; Lee KS; Sim SH; Park KH; Kim JH; Nam BH; Kim HJ; Kim TY; Lee KH; Kim SB; Ahn JH; Lee S; Ro J
Cancer Res Treat; 2019 Jan; 51(1):43-52. PubMed ID: 29458237
[TBL] [Abstract][Full Text] [Related]
2. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
[TBL] [Abstract][Full Text] [Related]
3. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
Alsaloumi L; Shawagfeh S; Abdi A; Basgut B
Oncol Res Treat; 2020; 43(12):694-702. PubMed ID: 32950984
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Lee KS; Park IH; Nam BH; Ro J
Invest New Drugs; 2013 Feb; 31(1):152-9. PubMed ID: 22562702
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
Lee J; Kim HH; Ro SM; Yang JH
PLoS One; 2017; 12(2):e0171605. PubMed ID: 28234911
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
Yamamoto D; Sato N; Rai Y; Yamamoto Y; Saito M; Iwata H; Masuda N; Oura S; Watanabe J; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Feb; 161(3):473-482. PubMed ID: 28005247
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
9. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Baselga J; Zamagni C; Gómez P; Bermejo B; Nagai SE; Melichar B; Chan A; Mángel L; Bergh J; Costa F; Gómez HL; Gradishar WJ; Hudis CA; Rapoport BL; Roché H; Maeda P; Huang L; Meinhardt G; Zhang J; Schwartzberg LS
Clin Breast Cancer; 2017 Dec; 17(8):585-594.e4. PubMed ID: 28830796
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
11. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D
Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.
Hong JY; Park YH; Choi MK; Jung HA; Lee SJ; Ahn JS; Im YH
Clin Breast Cancer; 2015 Oct; 15(5):e287-92. PubMed ID: 25997855
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P
J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Dong N; Wu Y; Song C; Wang M; Jiao Y; Zhang S
J BUON; 2020; 25(3):1348-1353. PubMed ID: 32862575
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
16. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
17. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
Xu B; Sun T; Zhang Q; Zhang P; Yuan Z; Jiang Z; Wang X; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Shen K; Yu S; Li H; Tang L; Qiu R;
Ann Oncol; 2021 Feb; 32(2):218-228. PubMed ID: 33188874
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
